Loading…
Reported covered position: Sr Policy Advisor, Fellow: Rep. Robin Kelly; Sr Leg. Asst., Leg. Asst.: Rep. Sean Casten
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.) via ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.)
2026 · third_quarter · Q3
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; FY 2026 Appropriations; FY 2027 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Initiatives, Food is Medicine
Source: Senate LDA
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE
ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.) via ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.)
2026 · second_quarter · Q2
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; FY 2026 Appropriations; FY 2027 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Initiatives, Food is Medicine
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.) via ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.)
2026 · first_quarter · 1A
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; FY 2026 Appropriations; FY 2027 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.) via ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.)
2026 · first_quarter · Q1
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; FY 2026 Appropriations; FY 2027 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Initiatives.
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.) via ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.)
2025 · fourth_quarter · Q4
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; FY 2026 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.) via ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.)
2025 · third_quarter · Q3
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; Drug Pricing; Emergency Provider Relief Fund; FY 2026 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; NIH/Research Funding; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.) via ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.)
2025 · second_quarter · Q2
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; FY 2026 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; NIH/Research Funding; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.) via ADVOCATE HEALTH (FKA ADVOCATE AURORA HEALTH, INC.)
2025 · first_quarter · Q1
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; FY 2025 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Initiatives.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ADVOCATE AURORA HEALTH, INC. via ADVOCATE AURORA HEALTH, INC.
2024 · fourth_quarter · Q4
Centers for Medicare and Medicaid Innovation; Drug Pricing and Medicare Parts B and D; Medicaid Funding; Medicare Advantage; Medicare Hospital/Provider Reimbursement Policy; Medicare Regulatory Reform; Medicare Shared Savings Program; 340B Drug Pricing Program
340B Drug Pricing Program; Alternative Payment Models; Anti-Kickback Statute Reform; Artificial Intelligence; Behavioral Health; COVID-19; Drug Pricing; Emergency Provider Relief Fund; FY 2024 Appropriations; Graduate Medical Education; Health Care Innovation; Health Sector Cybersecurity; Health Workforce; Hospital at Home; Mental Health; Post-Acute and Home Health Care Payments; Stark Law Reform/Modernization; Surprise Billing/Price Transparency; Telehealth/Digital Health; Value-Based Purchasing Reimbursement
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE